The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
© 2023. The Author(s)..
Clinical trial endpoints must be carefully and intentionally selected so that the results of the trial can be used to inform policy- and decision-making. The relative importance of potential endpoints often depends on the stakeholder, with patients having different preferences to policymakers and regulators. The set up of clinical trials for COVID-19 was problematic, as endpoints that could be reasonably measured did not always match the efficacy endpoints usually required by guideline panels. Thus, different endpoints were used, which made the timely comparison and evaluation of interventions difficult. Here we discuss the evolution of the COVID-19 landscape and the effect this is having on the selection of consistent and measurable clinical trial endpoints. Using appropriate endpoints is crucial for researchers to offer the most reliable, valid, and interpretable results possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Communications medicine - 3(2023), 1 vom: 17. Apr., Seite 53 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thorlund, Kristian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s43856-023-00281-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355731584 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355731584 | ||
| 003 | DE-627 | ||
| 005 | 20240214232701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43856-023-00281-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM355731584 | ||
| 035 | |a (NLM)37069219 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thorlund, Kristian |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Clinical trial endpoints must be carefully and intentionally selected so that the results of the trial can be used to inform policy- and decision-making. The relative importance of potential endpoints often depends on the stakeholder, with patients having different preferences to policymakers and regulators. The set up of clinical trials for COVID-19 was problematic, as endpoints that could be reasonably measured did not always match the efficacy endpoints usually required by guideline panels. Thus, different endpoints were used, which made the timely comparison and evaluation of interventions difficult. Here we discuss the evolution of the COVID-19 landscape and the effect this is having on the selection of consistent and measurable clinical trial endpoints. Using appropriate endpoints is crucial for researchers to offer the most reliable, valid, and interpretable results possible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Smith, Davey |e verfasserin |4 aut | |
| 700 | 1 | |a Linsell, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a White, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Boulware, David |e verfasserin |4 aut | |
| 700 | 1 | |a Currier, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Harari, Ofir |e verfasserin |4 aut | |
| 700 | 1 | |a Lhomme, Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Strub-Wourgaft, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Adam, Stacey |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Edward |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Communications medicine |d 2021 |g 3(2023), 1 vom: 17. Apr., Seite 53 |w (DE-627)NLM330650033 |x 2730-664X |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2023 |g number:1 |g day:17 |g month:04 |g pages:53 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43856-023-00281-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2023 |e 1 |b 17 |c 04 |h 53 | ||